Follow The Filings

XRAY Dentsply Sirona Inc.

Health Care, filed as DENTSPLY SIRONA INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2, sold by 2

  • 4 Owners
  • Max 12.2%
  • $120M
  • 2 add 2 reduce

In 2026 Q2 Alex Roepers and John Rogers added to Dentsply Sirona, while First Eagle Investment Management and Cathie Wood trimmed.

Who owns this now

Largest portfolio weights among holders, up to 12.2% (Alex Roepers, Atlantic Investment Management). Not free-float ownership.

  1. Alex Roepers Add 12.2%
  2. John Rogers Add 0.85%
  3. First Eagle Investment Manage... Reduce 0.02%
  4. Cathie Wood Reduce 0.02%

Who owns XRAY

Sorted by value, long equity only, as of 2026 Q2.

History
John Rogers, Ariel Investments 0.85%, was 0.83% Add +25.7% 8,026,107 $85M History
Alex Roepers, Atlantic Investment Management 12.2%, was 4.1% Add +261.1% 2,203,000 $23M History
First Eagle Investment Management 0.02%, was 0.30% Reduce −94.4% 851,347 $9M History
Cathie Wood, Ark Investment Management 0.02%, was 0.03% Reduce −11.7% 235,538 $2.5M History

4 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by XRAY's executives, directors and 10% owners in the last 12 months, from their Form 4s

All XRAY insider trades
  • $1.7M bought by 9 insiders
  • $916K sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Jonathan Jay Mazelsky Director
    Buy
    $101K 10,000 shares at $10.14 +19% to stake
    Traded Jun 12 Filed Jun 18
    ↗
  2. Clyde Hosein Director
    Buy
    $65K 6,500 shares at $9.99 +10% to stake
    Traded Jun 15 Filed Jun 16
    ↗
  3. Brian P McKeon Director
    Buy
    $101K 10,000 shares at $10.12 New stake
    Traded Jun 12 Filed Jun 15
    ↗
  4. Brian T Gladden Director
    Buy
    $100K 9,985 shares at $10.02 +19% to stake
    Traded Jun 15 Filed Jun 15
    ↗
  5. Betsy D Holden Director
    Buy
    $100K 10,086 shares at $9.88 +13% to stake
    Traded Jun 11 Filed Jun 15
    ↗
  6. Michael J Barber Director
    Buy
    $150K 15,175 shares at $9.89 +37% to stake
    Traded Jun 11 Filed Jun 15
    ↗
  7. Gregory T Lucier Director
    Buy
    $187K 15,000 shares at $12.45 +30% to stake
    Traded Mar 9 Filed Mar 9
    ↗
  8. James D Forbes Director
    Buy
    $62K 5,000 shares at $12.48 +100% to stake
    Traded Mar 9 Filed Mar 9
    ↗
  9. Gregory T Lucier Director
    Buy
    $707K 50,000 shares at $14.15 New stake
    Traded Mar 2–3 Filed Mar 3
    ↗
  10. James D Forbes Director
    Buy
    $67K 5,000 shares at $13.47 New stake
    Traded Mar 3 Filed Mar 3
    ↗
  11. Gregory T Lucier Director
    Sale
    $916K 82,200 shares at $11.14 100% of stake
    Traded Dec 8, 2025 Filed Dec 10, 2025
    ↗
  12. Leslie F Varon Director
    Buy
    $100K 9,337 shares at $10.71 +19% to stake
    Traded Nov 24, 2025 Filed Nov 25, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 35 stock grants, 14 share withholdings for taxes, and 2 gifts.

Congress

1 member of Congress traded XRAY in the last three years: 0 buys and 2 sales.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Sell $1K–$15K Jan 8, 2025 filed Feb 11, 2025
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Partial sale $1K–$15K Jan 7, 2025 filed Feb 11, 2025

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
8-K 1.01,2.03,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K/A 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 13 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $3.96B $3.79B $3.68B
Gross profit $2.09B $1.96B $1.84B
Gross margin * 52.6% 51.6% 50.0%
Net income -$132M -$910M -$598M
Net margin * -3.3% -24.0% -16.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.97B $1.75B $2.02B
Total non-current assets * $5.4B $4.01B $3.41B
Total assets $7.37B $5.75B $5.43B
Total current liabilities $1.42B $1.59B $1.34B
Total non-current liabilities * $2.65B $2.22B $2.75B
Total equity $3.29B $1.94B $1.34B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $377M $461M $235M
Cash from investing -$89M -$197M -$132M
Cash from financing -$307M -$302M -$80M
Net change in cash -$31M -$62M $54M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.